Apalutamide treatment for nonmetastatic, castration-resistant prostate cancer: a cost-effectiveness analysis of apalutamide plus androgen-deprivation therapy compared to androgen-deprivation therapy plus placebo

Additional Metadata
Keywords	Cost-effectiveness analysis;Nonmetastatic castration-resistant prostate cancer;Apalutamide
Thesis Advisor	Holleman, M.S.
Persistent URL	hdl.handle.net/2105/62438
Series	Master Health Economics, Policy and Law
Organisation	Erasmus School of Health Policy & Management
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Ronde, M.E.S. de. (2021, August 17). Apalutamide treatment for nonmetastatic, castration-resistant prostate cancer: a cost-effectiveness analysis of apalutamide plus androgen-deprivation therapy compared to androgen-deprivation therapy plus placebo. Master Health Economics, Policy and Law. Retrieved from http://hdl.handle.net/2105/62438

Publication